Crescentic glomerulonephritis in children
Data on patients with crescentic glomerulonephritis (greater than 50% glomeruli with crescents), referred to the Hospital for Sick Children during the past 13 years, were reviewed. Thirty patients (13 male, 17 female) aged 3.7-15.7 years (mean 9.5) were evaluated. Initial clinical features included:...
Gespeichert in:
Veröffentlicht in: | Pediatric nephrology (Berlin, West) West), 1992-05, Vol.6 (3), p.231-235 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 235 |
---|---|
container_issue | 3 |
container_start_page | 231 |
container_title | Pediatric nephrology (Berlin, West) |
container_volume | 6 |
creator | JARDIM, H. M. P. F RISDON, R. A BARRATT, T. M DILLON, M. J |
description | Data on patients with crescentic glomerulonephritis (greater than 50% glomeruli with crescents), referred to the Hospital for Sick Children during the past 13 years, were reviewed. Thirty patients (13 male, 17 female) aged 3.7-15.7 years (mean 9.5) were evaluated. Initial clinical features included: oedema (24/30), hypertension (19/30), gross haematuria (15/30), oliguria (15/30) and a decreased glomerular filtration rate (GFR less than 30 ml/min per 1.73 m2) (22/30). Henoch-Schönlein purpura was present in 9 patients, microscopic polyarteritis in 3, polyarteritis nodosa in 1, Wegener's granulomatosis in 1, systemic lupus erythematosus in 1, post-streptococcal glomerulonephritis in 2, mesangiocapillary glomerulonephritis in 7, anti-glomerular basement membrane glomerulonephritis in 2, and 4 were idiopathic. In 10 patients 50%-79% of glomeruli were affected by crescentic changes (group 1) and in the remaining 20, 80% or more (group 2). The crescents were cellular, fibrocellular or fibrous, and the degree of sclerosis was assessed. Patients in both groups were treated with plasma exchange, corticosteroids, anticoagulants, cyclophosphamide and azathioprine in different combinations. On follow-up, 3 patients were dead, 1 was lost to follow-up, 12 were on dialysis/transplant programmes, 4 had a GFR of less than 30 and 10 a GFR of more than 30 ml/min per 1.73 m2. In our experience, 50% progressed to end-stage renal failure. The interval between disease onset and start of treatment was a prognostic factor for outcome. Fibrous crescents were associated with a worse outcome than fibrocellular crescents (P less than 0.05). Outcome was not, however, related to the percentage of glomeruli affected (P greater than 0.05). |
doi_str_mv | 10.1007/BF00878354 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00878354</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1352123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-83d95b42730fb249872bb3e362bb1b93b3f919dc903a7ab105e273202380c113</originalsourceid><addsrcrecordid>eNpFzzFPwzAUBGALgUooLOxIGVhACrznF9f2SCsKSJVYOnSLbMehRmka2e3AvyeoFZ1uuE8nHWO3CE8IIJ-ncwAlFYnyjGVYEi9Qq9U5y0ATFlDi6pJdpfQNAxNqMmIjJMGRU8YeZtEn57tdcPlXu934uG-3ne_XMexCykOXu3Vo6-i7a3bRmDb5m2OO2XL-upy9F4vPt4_Zy6JwhLgrFNVa2JJLgsbyUivJrSVPkyHQarLUaNS100BGGosg_GA5cFLgEGnMHg-zLm5Tir6p-hg2Jv5UCNXf2-r0dsB3B9zv7cbXJ3q4N_T3x94kZ9omms6F9M-EkBMgSb9291oO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Crescentic glomerulonephritis in children</title><source>MEDLINE</source><source>Springer Journals</source><creator>JARDIM, H. M. P. F ; RISDON, R. A ; BARRATT, T. M ; DILLON, M. J</creator><creatorcontrib>JARDIM, H. M. P. F ; RISDON, R. A ; BARRATT, T. M ; DILLON, M. J</creatorcontrib><description>Data on patients with crescentic glomerulonephritis (greater than 50% glomeruli with crescents), referred to the Hospital for Sick Children during the past 13 years, were reviewed. Thirty patients (13 male, 17 female) aged 3.7-15.7 years (mean 9.5) were evaluated. Initial clinical features included: oedema (24/30), hypertension (19/30), gross haematuria (15/30), oliguria (15/30) and a decreased glomerular filtration rate (GFR less than 30 ml/min per 1.73 m2) (22/30). Henoch-Schönlein purpura was present in 9 patients, microscopic polyarteritis in 3, polyarteritis nodosa in 1, Wegener's granulomatosis in 1, systemic lupus erythematosus in 1, post-streptococcal glomerulonephritis in 2, mesangiocapillary glomerulonephritis in 7, anti-glomerular basement membrane glomerulonephritis in 2, and 4 were idiopathic. In 10 patients 50%-79% of glomeruli were affected by crescentic changes (group 1) and in the remaining 20, 80% or more (group 2). The crescents were cellular, fibrocellular or fibrous, and the degree of sclerosis was assessed. Patients in both groups were treated with plasma exchange, corticosteroids, anticoagulants, cyclophosphamide and azathioprine in different combinations. On follow-up, 3 patients were dead, 1 was lost to follow-up, 12 were on dialysis/transplant programmes, 4 had a GFR of less than 30 and 10 a GFR of more than 30 ml/min per 1.73 m2. In our experience, 50% progressed to end-stage renal failure. The interval between disease onset and start of treatment was a prognostic factor for outcome. Fibrous crescents were associated with a worse outcome than fibrocellular crescents (P less than 0.05). Outcome was not, however, related to the percentage of glomeruli affected (P greater than 0.05).</description><identifier>ISSN: 0931-041X</identifier><identifier>EISSN: 1432-198X</identifier><identifier>DOI: 10.1007/BF00878354</identifier><identifier>PMID: 1352123</identifier><identifier>CODEN: PENED3</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adolescent ; Adrenal Cortex Hormones - therapeutic use ; Anticoagulants - therapeutic use ; Azathioprine - therapeutic use ; Biological and medical sciences ; Child ; Child, Preschool ; Cyclophosphamide - therapeutic use ; Female ; Glomerular Filtration Rate - physiology ; Glomerulonephritis ; Glomerulonephritis - complications ; Glomerulonephritis - drug therapy ; Glomerulonephritis - pathology ; Glomerulonephritis, Membranoproliferative - complications ; Glomerulonephritis, Membranoproliferative - drug therapy ; Glomerulonephritis, Membranoproliferative - pathology ; Granulomatosis with Polyangiitis - complications ; Granulomatosis with Polyangiitis - pathology ; Granulomatosis with Polyangiitis - physiopathology ; Hematuria - etiology ; Hematuria - physiopathology ; Humans ; Hypertension - etiology ; Hypertension - physiopathology ; Kidney - drug effects ; Kidney - pathology ; Kidney - physiopathology ; London ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - pathology ; Lupus Erythematosus, Systemic - physiopathology ; Male ; Medical sciences ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Polyarteritis Nodosa - complications ; Polyarteritis Nodosa - pathology ; Polyarteritis Nodosa - physiopathology ; Prognosis ; Purpura, Schoenlein-Henoch - complications ; Purpura, Schoenlein-Henoch - drug therapy ; Purpura, Schoenlein-Henoch - pathology ; Vasculitis - complications ; Vasculitis - drug therapy ; Vasculitis - pathology</subject><ispartof>Pediatric nephrology (Berlin, West), 1992-05, Vol.6 (3), p.231-235</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-83d95b42730fb249872bb3e362bb1b93b3f919dc903a7ab105e273202380c113</citedby><cites>FETCH-LOGICAL-c311t-83d95b42730fb249872bb3e362bb1b93b3f919dc903a7ab105e273202380c113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5576037$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1352123$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JARDIM, H. M. P. F</creatorcontrib><creatorcontrib>RISDON, R. A</creatorcontrib><creatorcontrib>BARRATT, T. M</creatorcontrib><creatorcontrib>DILLON, M. J</creatorcontrib><title>Crescentic glomerulonephritis in children</title><title>Pediatric nephrology (Berlin, West)</title><addtitle>Pediatr Nephrol</addtitle><description>Data on patients with crescentic glomerulonephritis (greater than 50% glomeruli with crescents), referred to the Hospital for Sick Children during the past 13 years, were reviewed. Thirty patients (13 male, 17 female) aged 3.7-15.7 years (mean 9.5) were evaluated. Initial clinical features included: oedema (24/30), hypertension (19/30), gross haematuria (15/30), oliguria (15/30) and a decreased glomerular filtration rate (GFR less than 30 ml/min per 1.73 m2) (22/30). Henoch-Schönlein purpura was present in 9 patients, microscopic polyarteritis in 3, polyarteritis nodosa in 1, Wegener's granulomatosis in 1, systemic lupus erythematosus in 1, post-streptococcal glomerulonephritis in 2, mesangiocapillary glomerulonephritis in 7, anti-glomerular basement membrane glomerulonephritis in 2, and 4 were idiopathic. In 10 patients 50%-79% of glomeruli were affected by crescentic changes (group 1) and in the remaining 20, 80% or more (group 2). The crescents were cellular, fibrocellular or fibrous, and the degree of sclerosis was assessed. Patients in both groups were treated with plasma exchange, corticosteroids, anticoagulants, cyclophosphamide and azathioprine in different combinations. On follow-up, 3 patients were dead, 1 was lost to follow-up, 12 were on dialysis/transplant programmes, 4 had a GFR of less than 30 and 10 a GFR of more than 30 ml/min per 1.73 m2. In our experience, 50% progressed to end-stage renal failure. The interval between disease onset and start of treatment was a prognostic factor for outcome. Fibrous crescents were associated with a worse outcome than fibrocellular crescents (P less than 0.05). Outcome was not, however, related to the percentage of glomeruli affected (P greater than 0.05).</description><subject>Adolescent</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Anticoagulants - therapeutic use</subject><subject>Azathioprine - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Female</subject><subject>Glomerular Filtration Rate - physiology</subject><subject>Glomerulonephritis</subject><subject>Glomerulonephritis - complications</subject><subject>Glomerulonephritis - drug therapy</subject><subject>Glomerulonephritis - pathology</subject><subject>Glomerulonephritis, Membranoproliferative - complications</subject><subject>Glomerulonephritis, Membranoproliferative - drug therapy</subject><subject>Glomerulonephritis, Membranoproliferative - pathology</subject><subject>Granulomatosis with Polyangiitis - complications</subject><subject>Granulomatosis with Polyangiitis - pathology</subject><subject>Granulomatosis with Polyangiitis - physiopathology</subject><subject>Hematuria - etiology</subject><subject>Hematuria - physiopathology</subject><subject>Humans</subject><subject>Hypertension - etiology</subject><subject>Hypertension - physiopathology</subject><subject>Kidney - drug effects</subject><subject>Kidney - pathology</subject><subject>Kidney - physiopathology</subject><subject>London</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - pathology</subject><subject>Lupus Erythematosus, Systemic - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Polyarteritis Nodosa - complications</subject><subject>Polyarteritis Nodosa - pathology</subject><subject>Polyarteritis Nodosa - physiopathology</subject><subject>Prognosis</subject><subject>Purpura, Schoenlein-Henoch - complications</subject><subject>Purpura, Schoenlein-Henoch - drug therapy</subject><subject>Purpura, Schoenlein-Henoch - pathology</subject><subject>Vasculitis - complications</subject><subject>Vasculitis - drug therapy</subject><subject>Vasculitis - pathology</subject><issn>0931-041X</issn><issn>1432-198X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFzzFPwzAUBGALgUooLOxIGVhACrznF9f2SCsKSJVYOnSLbMehRmka2e3AvyeoFZ1uuE8nHWO3CE8IIJ-ncwAlFYnyjGVYEi9Qq9U5y0ATFlDi6pJdpfQNAxNqMmIjJMGRU8YeZtEn57tdcPlXu934uG-3ne_XMexCykOXu3Vo6-i7a3bRmDb5m2OO2XL-upy9F4vPt4_Zy6JwhLgrFNVa2JJLgsbyUivJrSVPkyHQarLUaNS100BGGosg_GA5cFLgEGnMHg-zLm5Tir6p-hg2Jv5UCNXf2-r0dsB3B9zv7cbXJ3q4N_T3x94kZ9omms6F9M-EkBMgSb9291oO</recordid><startdate>19920501</startdate><enddate>19920501</enddate><creator>JARDIM, H. M. P. F</creator><creator>RISDON, R. A</creator><creator>BARRATT, T. M</creator><creator>DILLON, M. J</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19920501</creationdate><title>Crescentic glomerulonephritis in children</title><author>JARDIM, H. M. P. F ; RISDON, R. A ; BARRATT, T. M ; DILLON, M. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-83d95b42730fb249872bb3e362bb1b93b3f919dc903a7ab105e273202380c113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adolescent</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Anticoagulants - therapeutic use</topic><topic>Azathioprine - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Female</topic><topic>Glomerular Filtration Rate - physiology</topic><topic>Glomerulonephritis</topic><topic>Glomerulonephritis - complications</topic><topic>Glomerulonephritis - drug therapy</topic><topic>Glomerulonephritis - pathology</topic><topic>Glomerulonephritis, Membranoproliferative - complications</topic><topic>Glomerulonephritis, Membranoproliferative - drug therapy</topic><topic>Glomerulonephritis, Membranoproliferative - pathology</topic><topic>Granulomatosis with Polyangiitis - complications</topic><topic>Granulomatosis with Polyangiitis - pathology</topic><topic>Granulomatosis with Polyangiitis - physiopathology</topic><topic>Hematuria - etiology</topic><topic>Hematuria - physiopathology</topic><topic>Humans</topic><topic>Hypertension - etiology</topic><topic>Hypertension - physiopathology</topic><topic>Kidney - drug effects</topic><topic>Kidney - pathology</topic><topic>Kidney - physiopathology</topic><topic>London</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - pathology</topic><topic>Lupus Erythematosus, Systemic - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Polyarteritis Nodosa - complications</topic><topic>Polyarteritis Nodosa - pathology</topic><topic>Polyarteritis Nodosa - physiopathology</topic><topic>Prognosis</topic><topic>Purpura, Schoenlein-Henoch - complications</topic><topic>Purpura, Schoenlein-Henoch - drug therapy</topic><topic>Purpura, Schoenlein-Henoch - pathology</topic><topic>Vasculitis - complications</topic><topic>Vasculitis - drug therapy</topic><topic>Vasculitis - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JARDIM, H. M. P. F</creatorcontrib><creatorcontrib>RISDON, R. A</creatorcontrib><creatorcontrib>BARRATT, T. M</creatorcontrib><creatorcontrib>DILLON, M. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pediatric nephrology (Berlin, West)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JARDIM, H. M. P. F</au><au>RISDON, R. A</au><au>BARRATT, T. M</au><au>DILLON, M. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Crescentic glomerulonephritis in children</atitle><jtitle>Pediatric nephrology (Berlin, West)</jtitle><addtitle>Pediatr Nephrol</addtitle><date>1992-05-01</date><risdate>1992</risdate><volume>6</volume><issue>3</issue><spage>231</spage><epage>235</epage><pages>231-235</pages><issn>0931-041X</issn><eissn>1432-198X</eissn><coden>PENED3</coden><abstract>Data on patients with crescentic glomerulonephritis (greater than 50% glomeruli with crescents), referred to the Hospital for Sick Children during the past 13 years, were reviewed. Thirty patients (13 male, 17 female) aged 3.7-15.7 years (mean 9.5) were evaluated. Initial clinical features included: oedema (24/30), hypertension (19/30), gross haematuria (15/30), oliguria (15/30) and a decreased glomerular filtration rate (GFR less than 30 ml/min per 1.73 m2) (22/30). Henoch-Schönlein purpura was present in 9 patients, microscopic polyarteritis in 3, polyarteritis nodosa in 1, Wegener's granulomatosis in 1, systemic lupus erythematosus in 1, post-streptococcal glomerulonephritis in 2, mesangiocapillary glomerulonephritis in 7, anti-glomerular basement membrane glomerulonephritis in 2, and 4 were idiopathic. In 10 patients 50%-79% of glomeruli were affected by crescentic changes (group 1) and in the remaining 20, 80% or more (group 2). The crescents were cellular, fibrocellular or fibrous, and the degree of sclerosis was assessed. Patients in both groups were treated with plasma exchange, corticosteroids, anticoagulants, cyclophosphamide and azathioprine in different combinations. On follow-up, 3 patients were dead, 1 was lost to follow-up, 12 were on dialysis/transplant programmes, 4 had a GFR of less than 30 and 10 a GFR of more than 30 ml/min per 1.73 m2. In our experience, 50% progressed to end-stage renal failure. The interval between disease onset and start of treatment was a prognostic factor for outcome. Fibrous crescents were associated with a worse outcome than fibrocellular crescents (P less than 0.05). Outcome was not, however, related to the percentage of glomeruli affected (P greater than 0.05).</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>1352123</pmid><doi>10.1007/BF00878354</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0931-041X |
ispartof | Pediatric nephrology (Berlin, West), 1992-05, Vol.6 (3), p.231-235 |
issn | 0931-041X 1432-198X |
language | eng |
recordid | cdi_crossref_primary_10_1007_BF00878354 |
source | MEDLINE; Springer Journals |
subjects | Adolescent Adrenal Cortex Hormones - therapeutic use Anticoagulants - therapeutic use Azathioprine - therapeutic use Biological and medical sciences Child Child, Preschool Cyclophosphamide - therapeutic use Female Glomerular Filtration Rate - physiology Glomerulonephritis Glomerulonephritis - complications Glomerulonephritis - drug therapy Glomerulonephritis - pathology Glomerulonephritis, Membranoproliferative - complications Glomerulonephritis, Membranoproliferative - drug therapy Glomerulonephritis, Membranoproliferative - pathology Granulomatosis with Polyangiitis - complications Granulomatosis with Polyangiitis - pathology Granulomatosis with Polyangiitis - physiopathology Hematuria - etiology Hematuria - physiopathology Humans Hypertension - etiology Hypertension - physiopathology Kidney - drug effects Kidney - pathology Kidney - physiopathology London Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - pathology Lupus Erythematosus, Systemic - physiopathology Male Medical sciences Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Polyarteritis Nodosa - complications Polyarteritis Nodosa - pathology Polyarteritis Nodosa - physiopathology Prognosis Purpura, Schoenlein-Henoch - complications Purpura, Schoenlein-Henoch - drug therapy Purpura, Schoenlein-Henoch - pathology Vasculitis - complications Vasculitis - drug therapy Vasculitis - pathology |
title | Crescentic glomerulonephritis in children |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A12%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Crescentic%20glomerulonephritis%20in%20children&rft.jtitle=Pediatric%20nephrology%20(Berlin,%20West)&rft.au=JARDIM,%20H.%20M.%20P.%20F&rft.date=1992-05-01&rft.volume=6&rft.issue=3&rft.spage=231&rft.epage=235&rft.pages=231-235&rft.issn=0931-041X&rft.eissn=1432-198X&rft.coden=PENED3&rft_id=info:doi/10.1007/BF00878354&rft_dat=%3Cpubmed_cross%3E1352123%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1352123&rfr_iscdi=true |